Pharmacotherapy for Patients with Personality Disorders

Experiences from a Group Analytic Treatment Program
  • S. Friis
  • T. Wilberg
  • T. Dammen
  • Ø. Urnes


There is an increasing interest in the pharmacological treatment of personality disorders. Despite the experience that psychotropic drugs often have only a modest effect on patients with personality disorders, medication has been suggested as an important adjunct to the overall treatment of these patients (Gitlin, 1993; Soloff, 1994). According to various conceptualisations of personality pathology, one may apply different strategies in the pharmacological treatment of personality disordered patients (Gitlin, 1993). Treatment may be directed towards various personality disorder categories, or specific symptom clusters within or across disorders, some of which have been suggested to have a biological substrate (Tuinier and Verhoeven, 1995; Soloff, 1994). The symptom clusters most frequently cited are affective instability, impulsivity, and aggressiveness, anxiety, and inhibition, and cognition and perception (DeBattista and Glick, 1995). A third alternative is to treat associated axis I disorders. However, in the presence of personality pathology the response to pharmacological treatment of axis I disorders is less pronounced (Reich and Vasile, 1993; Shea, Widiger, and Klein, 1992).


Borderline Personality Disorder Eating Disorder Mood Disorder Personality Disorder Social Phobia 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. American Psychiatric Association, 1994, Global assessment of functioning scale (GAF Scale). Diagnostic and Statistical Manual of Mental Disorders, 4th ed., Washington D.C.Google Scholar
  2. Coccaro, E.F., Astill, J.L., Herbert, J.L., and Scut, A.G., 1990, Fluoxetine treatment of impulsive aggression in DSM-III-R personality disorder patients, J. Clin. Psychopharmacol. 10: 373–375.PubMedCrossRefGoogle Scholar
  3. Cornelius, J.R., Soloff, P.H., Perel, J.M., and Ulrich, R.F., 1990, Fluoxetine trial in borderline personality disorder, Psychopharmacol. Bull. 26: 151–154.PubMedGoogle Scholar
  4. Cornelius, J.R., Soloff, P.H., Perel, J.M., and Ulrich, R.E,1993, Continuation pharmacotherapy of borderline personality disorder with haloperidol and phenelzine, Am. J. Psychiatry 150: 1843–1848.PubMedGoogle Scholar
  5. DeBattista, C. and Glick, I.D., 1995, Pharmacotherapy of personality disorders, Current Opinion in Psychiatry 8: 102–105.CrossRefGoogle Scholar
  6. Derogatis, L.R., 1977, The SCL-90: administration, scoring, and procedures manual-II for the revised version, Clinical Psychometric Research, Baltimore.Google Scholar
  7. Gitlin, M.J., 1993, Pharmacotherapy of personality disorders: conceptual framework and clinical strategies, J. Clin. Psychopharmacol. 13: 343–353.PubMedGoogle Scholar
  8. Goldberg, S.C., Schulz, C., Schulz, P.M., Resnick, R.J., Hamer, R.M., and Friedel, R.O., 1986, Borderline and schizotypal personality disorders treated with low-dose thiothixene vs. Placebo, Arch. Gen. Psychiatry 43: 680–686.PubMedCrossRefGoogle Scholar
  9. Hymowitz, P., Frances, A., Jacobsberg, L.B., Sickles, M., and Hoyt, R., 1986, Neuroleptic treatment of schizo-typal personality disorders, Compr. Psychiatry 27: 267–271.PubMedCrossRefGoogle Scholar
  10. Karterud, S., Friis, S., Irion, T., Mehlum, L., Vaglum, E, and Vaglum, S., 1995, A SCL-90-R derived index of the severity of personality disorders, J. Pers. Dis. 9: 112–123.CrossRefGoogle Scholar
  11. Karterud, S., Pedersen, G., Friis, S., Urnes, 0., Irion, T., Brabrand, J., Falkum, L.R., and LeirvAg, H., 1998, The Norwegian Network of psychotherapeutic day hospitals. Ther. Comm. 19: 15–28.Google Scholar
  12. Karterud, S., Vaglum, S., Friis, S., Irion, T., Johns, S., and Vaglum, E, 1992, Day hospital therapeutic community treatment for patients with personality disorders. An empirical evaluation of the containment function, J. Nerv. Ment. Dis. 180: 238–243.PubMedCrossRefGoogle Scholar
  13. Kavoussi, R.J., Liu, J., and Coccaro, E.E, 1994, An open trial of sertraline in personality disordered patients with impulsive aggression, J. Clin. Psychiatry 55: 137–141.PubMedGoogle Scholar
  14. Markovitz, P.J., Calabrese, J.R., Schulz, S.C., and Meltzer, H.Y.,1991, Fluoxetine in the treatment of borderline and schizotypal personality disorders, Am. J. Psychiatry 148: 1064–1067.PubMedGoogle Scholar
  15. Mehlum, L., Friis, S., Irion, T., Johns, S., Karterud, S., Vaglum, P., and Vaglum, S., 1991, Personality disorders 2–5 years after treatment: a prospective follow-up study, Acta Psychiatr. Scand. 84: 72–77.PubMedCrossRefGoogle Scholar
  16. Mehlum, L., Friis, S., Vaglum, P., and Karterud, S., 1994, The longitudinal pattern of suicidal behaviour in borderline personality disorder: a prospective follow-up study, Acta Psychiatr. Scand. 90: 124–130.PubMedCrossRefGoogle Scholar
  17. Montgomery, S.A. and Montgomery, D., 1982, Pharmacological prevention of suicidal behavior, J. Affect. Disord. 4: 291–298.PubMedCrossRefGoogle Scholar
  18. Montgomery, S. and Asberg, M., 1979, A new depression scale designed to be sensitive to change, Br. J. Psychiatry 134: 382–389.PubMedCrossRefGoogle Scholar
  19. Nordern, M.J., 1989, Fluoxetine in borderline personality disorder, Prog. Neuro-Psychopharmacol. Biol. Psychiatry 13: 885–893.Google Scholar
  20. Piper, W.E., Joyce, A.S., Rosie, J.S., and Azim, H FA,1994, Psychological mindedness, work and outcome in day treatment, Int. J. Group Psychotherapy 44: 291–311.Google Scholar
  21. Ravindran, A.V., Bialik, R.J., and Lapierre, Y.D., 1994, Therapeutic efficacy of specific serotonin reuptake inhibitors ( SSRI) in dysthymia, Can. J. Psychiatry 39: 21–26.PubMedGoogle Scholar
  22. Reich, J.H. and Vasile, R.G., 1993, Effect of personality disorders on the treatment outcome of axis I conditions: an update, J. Nerv. Ment. Dis. 181: 475–484.PubMedCrossRefGoogle Scholar
  23. Rosenberg, R., 1994, Borderline states: pharmacotherapy and psychobiology of personality. A discussion of Soloff’s article, Acta Psychiatr. Scand. 89 (Suppl. 379): 56–60.Google Scholar
  24. Salzman, C., Wolfson, A.N., Schatsberg, A., Looper, J., Henke, R., Albanese, M., Schwartz, J., and Miyawaki, E., 1995, Effect of fiuoxetine on anger in symptomatic volunteers with borderline personality disorder, J. Clin. Pharmacol. 15: 23–29.Google Scholar
  25. Sato, T., Sakado, K., and Sato, S., 1993, Is there any specific personality disorder or personality disorder cluster that worsens the short-term treatment outcome of major depression? Acta Psychiatr. Scand. 88: 342–349.Google Scholar
  26. Serban, G. and Siegel, S., 1984, Response of borderline and schizotypal patients to small doses of thiothixene and haloperidol, Am. J. Psychiatry 141: 1455–1458.PubMedGoogle Scholar
  27. Shea, M.T., Pilkonis, E, Beckham, E., Collins, J.E, Elkin, I., Scotsky, S.M., and Docherty, J.E, 1990, Personality disorders and treatment outcome in the NIMH treatment of depression collaborative program, Am. J. Psychiatry 147: 711–718.PubMedGoogle Scholar
  28. Shea, M.T., Widiger, T.A., and Klein, M.H., 1992, Comorbidity of personality disorders and depression: implications for treatment, J. Consult. Clin. Psychol. 60: 857–868.PubMedCrossRefGoogle Scholar
  29. Soloff, P.H., 1994, Is there any drug treatment of choice for the borderline patient? Acta Psychiatr. Scand. 89 (Suppl. 379): 50–55.Google Scholar
  30. Soloff, P.H., Cornelius, J., George, A., Nathan, S., Perel, J.M., and Ulrich, R.E, 1993, Efficacy of phenelzine and haloperidol in borderline personality disorder, Arch. Gen. Psychiatry 50: 377–385.PubMedCrossRefGoogle Scholar
  31. Soloff, PH., George, A., Nathan, S., Schulz, P.M., Cornelius, J.R., Herring, J., and Perel, J.M., 1989, Amitiptyline versus haloperidol in borderliners: final outcomes and predictors of response, J. Clin. Psychopharmacol. 9: 238–246.PubMedCrossRefGoogle Scholar
  32. Stein, G., 1992, Drug treatment of the personality disorders, Br. J. Psychiatry 161: 167–184.PubMedCrossRefGoogle Scholar
  33. Tuinier, S. and Verhoeven, W.M.A., 1995, Dimensional classification and behavioral pharmacology of personality disorders; a review and hypothesis, European Neuropsychopharmacol. 5: 135–146.CrossRefGoogle Scholar
  34. Vaglum, P., Friis, S., Irion, T., Johns, S., Karterud, S., Larsen, E, and Vaglum, S., 1990, Treatment response of severe and non severe personality disorders in a therapeutic community day unit, J. Pers. Dis. 4: 161–172.CrossRefGoogle Scholar
  35. Vaglum, E, Friis, S., Vaglum, S., and Larsen, E, 1989, A comparison between personality disorder diagnoses in DSM-III and DSM-IIIR: Reliability, diagnostic overlap, predictive validity, Psychopathol. 22: 309–314.CrossRefGoogle Scholar
  36. Wilberg, T., Karterud, S., Urnes, 0., Pedersen, G., and Friis, S.,1998, Outcomes of Poorly Functioning Patients With Personality Disorders in a Day Treatment Program, Psychiatr. Serv. 49: 1462–1467.PubMedGoogle Scholar

Copyright information

© Springer Science+Business Media New York 1999

Authors and Affiliations

  • S. Friis
    • 1
  • T. Wilberg
    • 1
  • T. Dammen
    • 1
  • Ø. Urnes
    • 1
  1. 1.Department of PsychiatryUllevål University HospitalOsloNorway

Personalised recommendations